Markets

Vaccinex prices IPO at $12, the low end of the range

Vaccinex, which is developing antibody therapies to combat cancer and neurological diseases, raised $40 million by offering 3.3 million shares at $12, the low end of the range of $12 to $15. Vaccinex plans to list on the Nasdaq under the symbol VCNX. Oppenheimer & Co. and BTIG acted as lead managers on the deal.

The article Vaccinex prices IPO at $12, the low end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More